MAPLE GROVE, Minn., May 4, 2017 /PRNewswire/ -- NxThera, Inc., a medical device company pioneering the application of its convective radiofrequency thermotherapy technology to treat endourological conditions, was named a recipient of the 2017 Eureka! Innovation Awards, honoring the most innovative companies, products and ideas in Minnesota. Presented by the Minneapolis/St. Paul Business Journal, the goal of the Eureka! Innovation Awards is to highlight and recognize creative, progressive companies that are transforming their industries by the way they do business. NxThera will receive the award in the healthcare technology category during a recognition ceremony in June.
NxThera's Rezūm® System is a transformational thermotherapy to treat benign prostatic hyperplasia (BPH), or enlarged prostate, which is one of the top 10 most common and costly diseases in the U.S. The symptoms of BPH affect more than 12 million men aged 50 years or more, with nearly 800,000 new diagnoses each year. Men with BPH suffer significant quality of life issues, including waking up multiple times during the night to urinate, frequency, urgency, irregular and weak urinary flow, anxiety, challenges with sexual function and limitations in daily activities. Urologists use the Rezūm System to efficiently and effectively treat the obstructive prostate tissue causing BPH in an office or outpatient procedure. The treated tissue then is resorbed by the body's immune system which alleviates the symptoms of BPH and improve patients' quality of life and ability to urinate.
"We are honored to be recognized by the Minneapolis/St. Paul Business Journal with the Eureka! Innovation Award for our revolutionary Rezūm System," said Bob Paulson, president and CEO of NxThera. "This award is a testament to the vision of our founder, Michael Hoey, and the dedication to this vision and incredible contributions from every member of our team. NxThera is committed to transforming the lives of the tens of millions of men suffering from BPH globally with a minimally invasive treatment option that allows patients to return to their daily activities sooner than traditional, more invasive procedures. We also continue our development efforts and clinical studies to expand the application of our innovative convective thermotherapy platform to treat other endourological conditions such as prostate, kidney and bladder cancer, and overactive bladder."
For more information about the Rezūm System, visit www.Rezūm.com.
About NxThera and the Rezūm System
NxThera pioneered its convective radiofrequency thermotherapy platform technology to treat a variety of endourological conditions, beginning with BPH. NxThera's FDA-cleared Rezūm System is a next-generation transurethral needle ablation system using radiofrequency to create thermal energy that is convectively delivered to obstructive prostate tissue in targeted, precise thermotherapy treatments, with minimal discomfort, to improve the symptoms of BPH symptoms and quality of life. Founded in 2008, NxThera is located in Maple Grove, Minn. For more information, visit www.Rezūm.com.
SOURCE NxThera, Inc.